UPDATE 1-Pozen settles migraine drug suit with Teva

* Settles suit over generic version of Treximet

* Says litigation against other defendants to continue

* Pozen shares up 2 pct

April 14 (BestGrowthStock) – Pharmaceutical company Pozen Inc
(POZN.O: ) settled a suit over its Treximet migraine drug with
top generics maker Teva Pharmaceutical Industries Ltd
(TEVA.TA: ), opening the door to settlements with other
drugmakers.

Teva Pharmaceuticals USA had filed with the U.S. Food and
Drug Administration, seeking marketing approval for a generic
version of Treximet. Treximet is marketed by Pozen’s U.S.
licensee GlaxoSmithKline (GSK.L: ).

The settlement will conclude Pozen’s litigation with Teva,
but does not end the ongoing litigation against the other three
defendants, Par Pharmaceutical Inc (PRX.N: ), Alphapharm Pty Ltd,
and Dr. Reddys Laboratories Inc (REDY.BO: ), Pozen said in a
statement.

Teva will agree to be bound by the outcome of such
litigation or any resulting settlements with third parties,
Pozen said.

Shares of Pozen were up nearly 2 percent at $10.44 in
morning trade Wednesday on Nasdaq.

Stock Market News

(Reporting by Shailesh Kuber in Bangalore; Editing by Vinu
Pilakkott)

UPDATE 1-Pozen settles migraine drug suit with Teva